A dedicated team full with years of expertise and extensive connections with key opinion leaders and sites across the Asia-Pacific. We are your gateway to accelerated oncology trials and drug development.
Delivering cutting-edge solutions for our patients.
Quality in every capsule designed to elevate your well-being.
Streamlined clinical trial development where expertise meets efficiency.
The United States Food & Drug Administration has given their stamp of approval to four Investigational New Drug (IND) applications:
Offering efficacy in combating breast cancer. ABV-1501 aims to provide a personalized approach to TNBC treatment, potentially improving patient outcomes and survival rates.
More Info Coming Soon
ABV-1519 represents a new avenue for patients with NSCLC. We hope to not only extend survival but also enhance the quality of life through targeted therapy.
More Info Coming Soon
Pancreatic cancer has one of the lowest survival rates among major cancers, with only about 10% of patients surviving five years after diagnosis. ABV-1703's targeted approach holds promise in extending survival rates.
More Info Coming Soon
The complexities of MDS make it difficult to combat this disease. ABV-1702 may potentially provide more effective and tolerable treatment options.
More Info Coming SoonMaitake mushroom is a proven ally in the battle against cancer. It is naturally packed with potent bioactive compounds that have sparked tremendous interest in the medical community. Research suggests that Maitake extract may inhibit tumor growth, bolster immune function, and enhance the efficacy of conventional cancer therapies. It has the potential to mitigate chemotherapy side effects, such as nausea and immune suppression.
RichWorld Ltd. is a health technology company dedicated to creating innovative and more accessible healthcare solutions for a healthier future.
